



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited in the United States Postal Service as first class mail in the envelope addressed to: MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia, 22313-1450, on

Date of Deposit

Attorney

44,815 Reg. No.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Applicant : Gopi M. Venkatesh et al.

Application No. : 10/713,929

Filed: November 14, 2003

Title : MODIFIED RELEASE DOSAGE FORMS OF

SKELETAL MUSCLE RELAXANTS

Docket No. : 451194-101

Art Unit : 1615

MAIL STOP AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97(b) WITH CERTIFICATION UNDER 37 CFR §1.97(e)(1)

As provided under 37 CFR §1.97(b), this supplemental information disclosure statement is submitted prior to the issuance of the first Official action on the merits. This statement is accompanied by a Certification Under 37 CFR §1.97(e)(1).

Pursuant to 37 CFR §1.56, the Examiner's attention is directed to the references listed on the attached Information Disclosure Citation. Copies of all foreign patent documents and non-patent literature references are provided herewith.

As required under 37 CFR §1.97(e)(1), Applicant testifies that each item of information contained in this supplemental information disclosure statement was cited in

Application. No.: 10/713,929 Docket No.: 451194-101

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR §1.97(b) WITH CERTIFICATION UNDER 37 CFR §1.97(e)(1)

a communication from the International Search Authority in corresponding PCT International Application No. PCT/US2004/037266 not more than three months prior to the filing of this supplemental information disclosure statement. A copy of the International Search Report, issued June 14, 2005, is enclosed herewith for reference.

It is to be understood that the present submission of art is in no way intended to be a waiver of any arguments or defenses available to the applicant under the rules of the U.S. Patent and Trademark Office and the statutes of the United States.

No fee is required. The Commissioner is authorized to charge any additional fees required by this paper or to credit any overpayment to Deposit Account No. 20-0809.

Respectfully submitted:

3y: <u>/___</u>/

John F. Kane

Reg. No. 44,815

THOMPSON HINE LLP 2000 Courthouse Plaza N.E. 10 West Second Street Dayton, Ohio 45402-1758 Telephone: (937) 443-6816

Facsimile: (937) 443-6635

INFORMATION DISCLOSURE CITATION				et: 451194-101	Appln.	Appln. No. 10/713,929				
Page 1 of 1 O P E										
	# A B 2005		Appli	cant: Gopi M. Venkatesh et a	l					
JUL 0 8 2005 g			Filed	: November 14, 2003	p: 161 <u>5</u>					
\	TADEMARKS									
		U.S.	PATE	NT DOCUMENTS			_			
Examiner			ate	Name Ventouras		Class	Sub			
	4,728,513	03/	1988	1900 Veritouras						
							-			
				<u> </u>	1					
	FOR	EIGN	PATENT DOCUMENT					Trans		
Examiner	Document No.	D	ate	Country		Class	Sub	Υ	N	
	01/15668	03/2		Patent Cooperation Treaty				X		
	03/020242	03/2	003	Patent Cooperation Treaty				Х	-	
				γ					ļ	
							-			
								<u> </u>		
<u> </u>				Author, Title, Date, Pertinent						
				ustained-release granules o I Journal of Pharmaceutics,						
Evaminer:	-1-	Date	Cons	sidered:						

^{*} Examiner: Date Considered:

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.